Hemispherx Biopharma, Inc. (NYSE Amex: HEB) said the recently filed lawsuit is without merit. The lawsuit is based upon the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE